Poland's new draft pharmaceutical law addresses exclusivity
This article was originally published in SRA
Poland’s Ministry of Health has drafted a new pharmaceutical law, which is under public discussion until 18 August1.The most important difference in comparison to an earlier draft2 issued last year is an amendment to the data exclusivity period for innovative human medicinal products.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.